[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Smith+Nephew plc will publish its third‑quarter 2025 trading report on 6 November 2025 at 7:00am GMT / 2:00am EST. A conference call for financial analysts will follow at 8:30am GMT / 3:30am EST, with access details to be posted on the company’s investor website.

The global medical technology group (LSE: SN; NYSE: SNN) operates across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, and reported $5.8 billion in sales in 2024.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

October 16, 2025

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant’s name)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ✔         Form 40-F __

Timing of Smith+Nephew Third Quarter 2025 Trading Report

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, will announce its trading report for the third quarter ended 27 September 2025 on Thursday, 6 November 2025 at 7.00am GMT / 2.00am EST. This will be followed by a conference call for financial analysts at 8.30am GMT / 3.30am EST, details of which will be published on the Smith+Nephew website at https://www.smith-nephew.com/en/about-us/investors.

Enquiries

Investors/ Analysts

Emily Heaven/Cora McCallum                                          +44 (0) 1923 477433

Smith+Nephew

Media

Charles Reynolds                                                               +44 (0) 1923 477314

Smith+Nephew

LEI: 213800ZTMDN8S67S1H61

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

​For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Smith & Nephew plc
		(Registrant)
Date: October 16, 2025	By:	/s/ Helen Barraclough
		Helen Barraclough
		Company Secretary

FAQ

When will Smith+Nephew (SNN) release its Q3 2025 trading report?

The report will be released on 6 November 2025 at 7:00am GMT / 2:00am EST.

What time is Smith+Nephew’s analyst call for the Q3 2025 update?

The analyst call is at 8:30am GMT / 3:30am EST on the same day.

Where can I find access details for the Smith+Nephew (SNN) analyst call?

Details will be published on the company’s investor website at https://www.smith-nephew.com/en/about-us/investors.

What exchanges list Smith+Nephew and under which tickers?

Smith+Nephew is listed on the LSE: SN and NYSE: SNN.

What were Smith+Nephew’s 2024 annual sales?

The company reported $5.8 billion in sales in 2024.

What businesses does Smith+Nephew operate in?

Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.